{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T10:19:23Z","timestamp":1771237163869,"version":"3.50.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T00:00:00Z","timestamp":1694390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-023-02186-1","type":"journal-article","created":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T06:02:16Z","timestamp":1694412136000},"page":"683-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs"],"prefix":"10.1007","volume":"47","author":[{"given":"G.","family":"Corica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pirchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Milioto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Nista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Arecco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Mattioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. S.","family":"Auriemma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Cocchiara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Colao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Ferone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-9208","authenticated-orcid":false,"given":"F.","family":"Gatto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,11]]},"reference":[{"issue":"11","key":"2186_CR1","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1172\/JCI39375","volume":"119","author":"S Melmed","year":"2009","unstructured":"Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119(11):3189\u20133202. https:\/\/doi.org\/10.1172\/JCI39375","journal-title":"J Clin Invest"},{"issue":"2","key":"2186_CR2","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1530\/EJE-21-0216","volume":"185","author":"S Crisafulli","year":"2021","unstructured":"Crisafulli S, Luxi N, Sultana J et al (2021) Global epidemiology of acromegaly: a systematic review and meta-analysis. Eur J Endocrinol 185(2):251\u2013263. https:\/\/doi.org\/10.1530\/EJE-21-0216","journal-title":"Eur J Endocrinol"},{"issue":"24","key":"2186_CR3","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1056\/NEJMra062453","volume":"355","author":"S Melmed","year":"2006","unstructured":"Melmed S (2006) Medical progress: Acromegaly. N Engl J Med 355(24):2558\u20132573. https:\/\/doi.org\/10.1056\/NEJMra062453","journal-title":"N Engl J Med"},{"issue":"2","key":"2186_CR4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1530\/EJE-08-0267","volume":"159","author":"IM Holdaway","year":"2008","unstructured":"Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159(2):89\u201395. https:\/\/doi.org\/10.1530\/EJE-08-0267","journal-title":"Eur J Endocrinol"},{"key":"2186_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/TCRM.S183360","volume":"16","author":"G Corica","year":"2020","unstructured":"Corica G, Ceraudo M, Campana C et al (2020) Octreotide-resistant acromegaly: challenges and solutions. Ther Clin Risk Manag 16:379\u2013391. https:\/\/doi.org\/10.2147\/TCRM.S183360","journal-title":"Ther Clin Risk Manag"},{"issue":"3","key":"2186_CR6","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s12020-018-1630-4","volume":"61","author":"F Gatto","year":"2018","unstructured":"Gatto F, Trifiro G, Lapi F et al (2018) Epidemiology of acromegaly in Italy: analysis from a large longitudinal primary care database. Endocrine 61(3):533\u2013541. https:\/\/doi.org\/10.1007\/s12020-018-1630-4","journal-title":"Endocrine"},{"issue":"9","key":"2186_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/s41574-018-0058-5","volume":"14","author":"S Melmed","year":"2018","unstructured":"Melmed S, Bronstein MD, Chanson P et al (2018) A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol 14(9):552\u2013561. https:\/\/doi.org\/10.1038\/s41574-018-0058-5","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2186_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/nrendo.2014.21","volume":"10","author":"A Giustina","year":"2014","unstructured":"Giustina A, Chanson P, Kleinberg D et al (2014) Expert consensus document: a consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10(4):243\u2013248. https:\/\/doi.org\/10.1038\/nrendo.2014.21","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"2186_CR9","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11154-019-09506-y","volume":"20","author":"F Gatto","year":"2019","unstructured":"Gatto F, Campana C, Cocchiara F et al (2019) Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord 20(3):365\u2013381. https:\/\/doi.org\/10.1007\/s11154-019-09506-y","journal-title":"Rev Endocr Metab Disord"},{"key":"2186_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa363","author":"G Mazziotti","year":"2020","unstructured":"Mazziotti G, Battista C, Maffezzoni F et al (2020) Treatment of acromegalic osteopathy in real-life clinical practice: the BAAC (Bone Active Drugs in Acromegaly) study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa363","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2186_CR11","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/neuros\/nyx020","volume":"81","author":"H Babu","year":"2017","unstructured":"Babu H, Ortega A, Nuno M et al (2017) Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors. Neurosurgery 81(2):357\u2013366. https:\/\/doi.org\/10.1093\/neuros\/nyx020","journal-title":"Neurosurgery"},{"issue":"3","key":"2186_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","volume":"19","author":"A Colao","year":"2016","unstructured":"Colao A, Auriemma RS, Pivonello R et al (2016) Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly. Pituitary 19(3):235\u2013247. https:\/\/doi.org\/10.1007\/s11102-015-0684-z","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1210\/er.2010-0002","volume":"32","author":"A Colao","year":"2011","unstructured":"Colao A, Auriemma RS, Lombardi G et al (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32(2):247\u2013271. https:\/\/doi.org\/10.1210\/er.2010-0002","journal-title":"Endocr Rev"},{"issue":"2","key":"2186_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1210\/clinem\/dgab726","volume":"107","author":"MR Gadelha","year":"2022","unstructured":"Gadelha MR, Wildemberg LE, Kasuki L (2022) The future of somatostatin receptor ligands in acromegaly. J Clin Endocrinol Metab 107(2):297\u2013308. https:\/\/doi.org\/10.1210\/clinem\/dgab726","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2186_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1007\/s11102-017-0791-0","volume":"20","author":"MR Gadelha","year":"2017","unstructured":"Gadelha MR, Wildemberg LE, Bronstein MD et al (2017) Somatostatin receptor ligands in the treatment of acromegaly. Pituitary 20(1):100\u2013108. https:\/\/doi.org\/10.1007\/s11102-017-0791-0","journal-title":"Pituitary"},{"issue":"1","key":"2186_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","volume":"24","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Biller BMK, Freda PU et al (2021) A pituitary society update to acromegaly management guidelines. Pituitary 24(1):1\u201313. https:\/\/doi.org\/10.1007\/s11102-020-01091-7","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR17","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s11102-021-01193-w","volume":"25","author":"F Cocchiara","year":"2022","unstructured":"Cocchiara F, Campana C, Nista F et al (2022) Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. Pituitary 25(2):246\u2013257. https:\/\/doi.org\/10.1007\/s11102-021-01193-w","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1530\/EJE-09-0372","volume":"161","author":"A Giustina","year":"2009","unstructured":"Giustina A, Bonadonna S, Bugari G et al (2009) High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 161(2):331\u2013338. https:\/\/doi.org\/10.1530\/EJE-09-0372","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2186_CR19","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2017-00142","volume":"102","author":"A Giustina","year":"2017","unstructured":"Giustina A, Mazziotti G, Cannavo S et al (2017) High-dose and high-frequency Lanreotide Autogel in acromegaly: a randomized Multicenter Study. J Clin Endocrinol Metab 102(7):2454\u20132464. https:\/\/doi.org\/10.1210\/jc.2017-00142","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2186_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1530\/EJE-07-0383","volume":"157","author":"A Colao","year":"2007","unstructured":"Colao A, Pivonello R, Auriemma RS et al (2007) Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 157(5):579\u2013587. https:\/\/doi.org\/10.1530\/EJE-07-0383","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2186_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","volume":"44","author":"RS Auriemma","year":"2015","unstructured":"Auriemma RS, Pivonello R, Ferreri L et al (2015) Cabergoline use for pituitary tumors and valvular disorders. Endocrinol Metab Clin North Am 44(1):89\u201397. https:\/\/doi.org\/10.1016\/j.ecl.2014.10.007","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2186_CR22","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1210\/jc.2010-2443","volume":"96","author":"L Sandret","year":"2011","unstructured":"Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96(5):1327\u20131335. https:\/\/doi.org\/10.1210\/jc.2010-2443","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2186_CR23","doi-asserted-by":"publisher","first-page":"646","DOI":"10.20945\/2359-3997000000195","volume":"63","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, van Meyel SWF, van der Lely AJ et al (2019) The position of combined medical treatment in acromegaly. Arch Endocrinol Metab 63(6):646\u2013652. https:\/\/doi.org\/10.20945\/2359-3997000000195","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2186_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1530\/EJE-21-0239","volume":"185","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Fuhrer-Sakel D, van der Lely AJ et al (2021) More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Eur J Endocrinol 185(4):525\u2013538. https:\/\/doi.org\/10.1530\/EJE-21-0239","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2186_CR25","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1210\/jc.2013-2480","volume":"99","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P et al (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab 99(3):791\u2013799. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2186_CR26","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","volume":"2","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T et al (2014) Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol 2(11):875\u2013884. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2186_CR27","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","volume":"24","author":"SL Samson","year":"2021","unstructured":"Samson SL, Gu F, Feldt-Rasmussen U et al (2021) Managing pasireotide-associated hyperglycemia: a randomized, open-label Phase IV study. Pituitary 24(6):887\u2013903. https:\/\/doi.org\/10.1007\/s11102-021-01161-4","journal-title":"Pituitary"},{"issue":"3","key":"2186_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11154-022-09710-3","volume":"23","author":"M Bolanowski","year":"2022","unstructured":"Bolanowski M, Kaluzny M, Witek P et al (2022) Pasireotide-a novel somatostatin receptor ligand after 20 years of use. Rev Endocr Metab Disord 23(3):601\u2013620. https:\/\/doi.org\/10.1007\/s11154-022-09710-3","journal-title":"Rev Endocr Metab Disord"},{"issue":"6","key":"2186_CR29","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1210\/jc.2018-01979","volume":"104","author":"EC Coopmans","year":"2019","unstructured":"Coopmans EC, Muhammad A, van der Lely AJ et al (2019) How to position pasireotide LAR treatment in acromegaly. J Clin Endocrinol Metab 104(6):1978\u20131988. https:\/\/doi.org\/10.1210\/jc.2018-01979","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2186_CR30","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1530\/eje.0.1460707","volume":"146","author":"C Bruns","year":"2002","unstructured":"Bruns C, Lewis I, Briner U et al (2002) SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 146(5):707\u2013716. https:\/\/doi.org\/10.1530\/eje.0.1460707","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2186_CR31","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-15-0391","volume":"174","author":"F Gatto","year":"2016","unstructured":"Gatto F, Biermasz NR, Feelders RA et al (2016) Low beta-arrestin expression correlates with the responsiveness to long-term somatostatin analog treatment in acromegaly. Eur J Endocrinol 174(5):651\u2013662. https:\/\/doi.org\/10.1530\/EJE-15-0391","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2186_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s11102-018-0926-y","volume":"22","author":"F Gatto","year":"2019","unstructured":"Gatto F, Arvigo M, Amaru J et al (2019) Cell specific interaction of pasireotide: review of preclinical studies in somatotroph and corticotroph pituitary cells. Pituitary 22(1):89\u201399. https:\/\/doi.org\/10.1007\/s11102-018-0926-y","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR33","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1210\/me.2009-0315","volume":"24","author":"F Poll","year":"2010","unstructured":"Poll F, Lehmann D, Illing S et al (2010) Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation. Mol Endocrinol 24(2):436\u2013446. https:\/\/doi.org\/10.1210\/me.2009-0315","journal-title":"Mol Endocrinol"},{"key":"2186_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20163940","author":"F Gatto","year":"2019","unstructured":"Gatto F, Barbieri F, Arvigo M et al (2019) Biological and biochemical basis of the differential efficacy of first and second generation somatostatin receptor ligands in neuroendocrine neoplasms. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms20163940","journal-title":"Int J Mol Sci"},{"issue":"1\u20132","key":"2186_CR35","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","volume":"286","author":"HA Schmid","year":"2008","unstructured":"Schmid HA (2008) Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol 286(1\u20132):69\u201374. https:\/\/doi.org\/10.1016\/j.mce.2007.09.006","journal-title":"Mol Cell Endocrinol"},{"key":"2186_CR36","doi-asserted-by":"publisher","first-page":"931","DOI":"10.3389\/fendo.2019.00931","volume":"10","author":"M Gadelha","year":"2019","unstructured":"Gadelha M, Bex M, Colao A et al (2019) Evaluation of the efficacy and safety of switching to pasireotide in patients with acromegaly inadequately controlled with first-generation somatostatin analogs. Front Endocrinol (Lausanne) 10:931. https:\/\/doi.org\/10.3389\/fendo.2019.00931","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2186_CR37","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1530\/EJE-19-0762","volume":"182","author":"A Colao","year":"2020","unstructured":"Colao A, Bronstein MD, Brue T et al (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study. Eur J Endocrinol 182(6):583. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"2186_CR38","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1210\/jc.2017-00135","volume":"102","author":"F Gatto","year":"2017","unstructured":"Gatto F, Feelders RA, Franck SE et al (2017) In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas. J Clin Endocrinol Metab 102(6):2009\u20132018. https:\/\/doi.org\/10.1210\/jc.2017-00135","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2186_CR39","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1530\/EC-19-0332","volume":"8","author":"H Lasolle","year":"2019","unstructured":"Lasolle H, Ferriere A, Vasiljevic A et al (2019) Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect 8(10):1383\u20131394. https:\/\/doi.org\/10.1530\/EC-19-0332","journal-title":"Endocr Connect"},{"key":"2186_CR40","doi-asserted-by":"publisher","first-page":"633944","DOI":"10.3389\/fendo.2021.633944","volume":"12","author":"P Witek","year":"2021","unstructured":"Witek P, Bolanowski M, Szamotulska K et al (2021) The effect of 6 months\u2019 treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne) 12:633944. https:\/\/doi.org\/10.3389\/fendo.2021.633944","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2186_CR41","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","volume":"62","author":"I Shimon","year":"2018","unstructured":"Shimon I, Adnan Z, Gorshtein A et al (2018) Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine 62(2):448\u2013455. https:\/\/doi.org\/10.1007\/s12020-018-1690-5","journal-title":"Endocrine"},{"issue":"1","key":"2186_CR42","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/s11102-021-01185-w","volume":"25","author":"M Stelmachowska-Banas","year":"2022","unstructured":"Stelmachowska-Banas M, Czajka-Oraniec I, Tomasik A et al (2022) Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary 25(1):180\u2013190. https:\/\/doi.org\/10.1007\/s11102-021-01185-w","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR43","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1210\/jc.2017-02017","volume":"103","author":"A Muhammad","year":"2018","unstructured":"Muhammad A, van der Lely AJ, Delhanty PJD et al (2018) Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE Study). J Clin Endocrinol Metab 103(2):586\u2013595. https:\/\/doi.org\/10.1210\/jc.2017-02017","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2186_CR44","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"C Practice","year":"2022","unstructured":"American Diabetes Association Professional Practice C, American Diabetes Association Professional Practice C, Practice C, Draznin B et al (2022) Classification and diagnosis of diabetes: standards of medical care in diabetes-2022. Diabetes Care 45(Suppl 1):S17\u2013S38. https:\/\/doi.org\/10.2337\/dc22-S002","journal-title":"Diabetes Care"},{"issue":"4","key":"2186_CR45","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","volume":"21","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A et al (2020) Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord 21(4):667\u2013678. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"issue":"3","key":"2186_CR46","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11102-018-0884-4","volume":"21","author":"MJ van Esdonk","year":"2018","unstructured":"van Esdonk MJ, van Zutphen EJM, Roelfsema F et al (2018) How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary 21(3):310\u2013322. https:\/\/doi.org\/10.1007\/s11102-018-0884-4","journal-title":"Pituitary"},{"issue":"2","key":"2186_CR47","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","volume":"10","author":"M Fleseriu","year":"2022","unstructured":"Fleseriu M, Dreval A, Bondar I et al (2022) Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial. Lancet Diabetes Endocrinol 10(2):102\u2013111. https:\/\/doi.org\/10.1016\/S2213-8587(21)00296-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2186_CR48","doi-asserted-by":"publisher","first-page":"627711","DOI":"10.3389\/fendo.2021.627711","volume":"12","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Molitch M, Dreval A et al (2021) Disease and treatment-related burden in patients with acromegaly who are biochemically controlled on injectable somatostatin receptor ligands. Front Endocrinol (Lausanne) 12:627711. https:\/\/doi.org\/10.3389\/fendo.2021.627711","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2186_CR49","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgz096","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkan A, Beckers A et al (2020) A consensus on the diagnosis and treatment of acromegaly comorbidities: an update. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgz096","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2186_CR50","doi-asserted-by":"publisher","first-page":"R89","DOI":"10.1530\/EJE-17-1006","volume":"178","author":"L Kasuki","year":"2018","unstructured":"Kasuki L, Wildemberg LE, Gadelha MR (2018) Management of endocrine disease: Personalized medicine in the treatment of acromegaly. Eur J Endocrinol 178(3):R89\u2013R100. https:\/\/doi.org\/10.1530\/EJE-17-1006","journal-title":"Eur J Endocrinol"},{"key":"2186_CR51","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad378","author":"M Gadelha","year":"2023","unstructured":"Gadelha M, Marques NV, Fialho C et al (2023) Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years\u2019 single-center real-world experience. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgad378","journal-title":"J Clin Endocrinol Metab"},{"key":"2186_CR52","doi-asserted-by":"publisher","first-page":"935759","DOI":"10.3389\/fendo.2022.935759","volume":"13","author":"A Mondin","year":"2022","unstructured":"Mondin A, Manara R, Voltan G et al (2022) Pasireotide-induced shrinkage in GH and ACTH secreting pituitary adenoma: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 13:935759. https:\/\/doi.org\/10.3389\/fendo.2022.935759","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2186_CR53","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/jc.2013-1771","volume":"98","author":"RR Henry","year":"2013","unstructured":"Henry RR, Ciaraldi TP, Armstrong D et al (2013) Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab 98(8):3446\u20133453. https:\/\/doi.org\/10.1210\/jc.2013-1771","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"2186_CR54","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1530\/EC-20-0361","volume":"9","author":"MR Gadelha","year":"2020","unstructured":"Gadelha MR, Gu F, Bronstein MD et al (2020) Risk factors and management of pasireotide-associated hyperglycemia in acromegaly. Endocr Connect 9(12):1178\u20131190. https:\/\/doi.org\/10.1530\/EC-20-0361","journal-title":"Endocr Connect"},{"issue":"1","key":"2186_CR55","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/cen.14750","volume":"98","author":"J Dal","year":"2023","unstructured":"Dal J, Rosendal C, Karmisholt J et al (2023) Sex difference in patients with controlled acromegaly-A multicentre survey. Clin Endocrinol (Oxf) 98(1):74\u201381. https:\/\/doi.org\/10.1111\/cen.14750","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2186_CR56","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11102-017-0797-7","volume":"20","author":"R Pivonello","year":"2017","unstructured":"Pivonello R, Auriemma RS, Grasso LF et al (2017) Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary 20(1):46\u201362. https:\/\/doi.org\/10.1007\/s11102-017-0797-7","journal-title":"Pituitary"},{"issue":"4","key":"2186_CR57","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11102-011-0365-5","volume":"15","author":"C Giordano","year":"2012","unstructured":"Giordano C, Ciresi A, Amato MC et al (2012) Clinical and metabolic effects of first-line treatment with somatostatin analogues or surgery in acromegaly: a retrospective and comparative study. Pituitary 15(4):539\u2013551. https:\/\/doi.org\/10.1007\/s11102-011-0365-5","journal-title":"Pituitary"},{"issue":"11","key":"2186_CR58","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1210\/jc.2014-2259","volume":"99","author":"C Reyes-Vidal","year":"2014","unstructured":"Reyes-Vidal C, Fernandez JC, Bruce JN et al (2014) Prospective study of surgical treatment of acromegaly: effects on ghrelin, weight, adiposity, and markers of CV risk. J Clin Endocrinol Metab 99(11):4124\u20134132. https:\/\/doi.org\/10.1210\/jc.2014-2259","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2186_CR59","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/cen.13285","volume":"86","author":"PJ Caron","year":"2017","unstructured":"Caron PJ, Petersenn S, Houchard A et al (2017) Glucose and lipid levels with lanreotide autogel 120 mg in treatment-naive patients with acromegaly: data from the PRIMARYS study. Clin Endocrinol (Oxf) 86(4):541\u2013551. https:\/\/doi.org\/10.1111\/cen.13285","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"8","key":"2186_CR60","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.clinthera.2014.06.006","volume":"36","author":"X Chen","year":"2014","unstructured":"Chen X, Shen G, Jiang J et al (2014) Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther 36(8):1196\u20131210. https:\/\/doi.org\/10.1016\/j.clinthera.2014.06.006","journal-title":"Clin Ther"},{"issue":"1","key":"2186_CR61","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s12020-018-1524-5","volume":"61","author":"A Albani","year":"2018","unstructured":"Albani A, Ferrau F, Ciresi A et al (2018) Pasireotide treatment reduces cardiometabolic risk in Cushing\u2019s disease patients: an Italian, multicenter study. Endocrine 61(1):118\u2013124. https:\/\/doi.org\/10.1007\/s12020-018-1524-5","journal-title":"Endocrine"},{"issue":"1","key":"2186_CR62","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40618-019-01077-8","volume":"43","author":"C Simeoli","year":"2020","unstructured":"Simeoli C, Ferrigno R, De Martino MC et al (2020) The treatment with pasireotide in Cushing\u2019s disease: effect of long-term treatment on clinical picture and metabolic profile and management of adverse events in the experience of a single center. J Endocrinol Invest 43(1):57\u201373. https:\/\/doi.org\/10.1007\/s40618-019-01077-8","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02186-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-023-02186-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-023-02186-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T17:30:11Z","timestamp":1709227811000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-023-02186-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,11]]},"references-count":62,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["2186"],"URL":"https:\/\/doi.org\/10.1007\/s40618-023-02186-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,11]]},"assertion":[{"value":"14 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Diego Ferone has been a speaker for and participated on advisory boards and received research grants from Novartis AAA, Ipsen, Camurus and Recordati. Diego Ferone is a member of the Editorial Board of Journal of Endocrinological Investigation. Annamaria Colao received research grants from Novo Nordisk and Ipsen. Rosario Pivonello has been the Principal Investigator of Clinical and\/or Translational Research Studies for Novartis, HRA Pharma, Ipsen, Shire, Corcept Therapeutics, Cortendo AB, Janssen Cilag, Camurus, Strongbridge, and Pfizer; Co-investigator of Research Studies for Pfizer; received research grants from Novartis, Pfizer, Ipsen, HRA Pharma, Shire, IBSA, Strongbridge Biopharma; has been an occasional consultant for Novartis, Ipsen, Pfizer, Shire, HRA Pharma, Cortendo AB, Ferring, Strongbridge Biopharma, Recordati, Corcept Therapeutics, Crinetics Pharmaceuticals, ARH Healthcare, Biohealth Italia; and has received fees and honoraria for presentations from Novartis, Shire, Pfizer and Recordati beyond the confines of this work. The other Authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the Institutional ethical committees and with the 1964 Helsinki declarations and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}